Modern Pediatrics. Ukraine. (2024). 2(138): 115-124. doi: 10.15574/SP.2024.138.115
Malska A. A.¹, Kurilyak O. B.², Klymyshyn Y. I.³, Rudenko N. M.^3
1Danylo Halytsky Lviv National Medical University, Ukraine
²Lviv Regional Children's Clinical Hospital "OKHMATDYT", Ukraine
³SI "Scientific and Practical Medical Center for Pediatric Cardiology and Cardiac Surgery of the Ministry of Health of Ukraine", Kyiv

For citation: Malska AA, Kurilyak OB, Klymyshyn YI, Rudenko NM. (2024). Modern approache to the diagnosis and treatment of Kawasaki disease (а literature review). Modern Pediatrics. Ukraine. 2(138): 115-124. doi: 10.15574/SP.2024.138.115.
Article received: Dec 25, 2023. Accepted for publication: Mar 12, 2024.

Kawasaki disease (KD) is a vasculitis of unknown origin, accompanied by fever and mucocutaneous syndrome, predominantly found in infants. KD is the most common cause of acquired heart disease in children in developed countries, which is complicated by the occurrence of coronary artery aneurysms in 25% of untreated patients due to coronary artery vasculitis.
The aim is to analyze the guidelines of the American Heart Association, the Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE), as well as Japanese instructions on modern approaches to the diagnosis and treatment of Kawasaki disease.
Clinical studies show that this rate decreases to ∼4% during treatment with intravenous immunoglobulin. Although some new studies show worse outcomes despite immunoglobulin treatment, especially in infants under 12 months of age. The complexity and heterogeneity of the course of KD, a wide differential diagnosis and the lack of a specific diagnostic tests are often serious obstacles on the way to diagnosis.
Taking into account some differences in American, European, and Japanese guidelines for the treatment of KD, we consider it appropriate to follow European guidelines, which are most similar to American ones and are best suited for Europeans.
The authors declare no conflict of interest.
Keywords: Kawasaki disease, complete Kawasaki disease, incomplete Kawasaki disease, prolonged fever, rash, coronary artery aneurysms, immunoglobulin, warfarin, children.

REFEENCES

1. Alves NR, Magalhães CM, Almeida RdFR, Santos RC, Gandolfi L, Pratesi R. (2011). Prospective study of Kawasaki disease complications: review of 115 cases. Rev Assoc Med Bras (1992). 57: 295-300. https://doi.org/10.1016/S0104-4230(11)70062-8; PMid:21691693

2. Baker AL, Lu M, Minich LL, Atz AM, Klein GL, Korsin R et al. (2009). Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 154: 592-595.e2. https://doi.org/10.1016/j.jpeds.2008.10.006; PMid:19038400 PMCid:PMC2745188

3. Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. (2006). Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. (4): CD004175. https://doi.org/10.1002/14651858.CD004175.pub2; PMid:17054199 PMCid:PMC8765111

4. Burns JC, Franco A. (2015). The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol. 11: 819-825. https://doi.org/10.1586/1744666X.2015.1044980; PMid:26099344 PMCid:PMC4985263

5. Cai Z, Zuo R, Liu Y. (2011). Characteristics of Kawasaki disease in older children. Clin Pediatr (Phila). 50: 952-956. https://doi.org/10.1177/0009922811409027; PMid:21628347

6. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 345: 1809-1817. https://doi.org/10.1056/NEJMoa003199; PMid:11752357

7. Chen S, Dong Y, Kiuchi MG et al. (2016). Coronary artery complication in Kawasaki disease and the importance of early intervention: a systematic review and meta-analysis. JAMA Pediatr. 170: 1156-1163. https://doi.org/10.1001/jamapediatrics.2016.2055; PMid:27749951

8. Coon ER, Wilkes J, Bratton SL, Srivastava R. (2018, Oct). Paediatric overdiagnosis modelled by coronary abnormality trends in Kawasaki disease. Arch Dis Child. 103(10): 937-941. Epub 2018 Feb 22. https://doi.org/10.1136/archdischild-2017-313694; PMid:29472194

9. Cotrufo M, de Feo M, de Sanctis L et al. (2002). Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol. 99: 35-40. https://doi.org/10.1016/S0029-7844(01)01658-1; PMid:11777507

10. De Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B et al. (2019,Apr). European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology. 58; 4: 672-682. https://doi.org/10.1093/rheumatology/key344; PMid:30535127

11. Dengler LD, Capparelli EV, Bastian JF, Bradley DJ, Glode MP, Santa S et al. (1998). Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J. 17: 478-481. https://doi.org/10.1097/00006454-199806000-00008; PMid:9655538

12. Durongpisitkul K et al. (1995).The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 96; 6: 1057-1061. https://doi.org/10.1542/peds.96.6.1057; PMid:7491221

13. Eleftheriou D, Levin M, Shingadia D et al. (2014). Management of Kawasaki disease. Arch Dis Child. 99: 74-83. https://doi.org/10.1136/archdischild-2012-302841; PMid:24162006 PMCid:PMC3888612

14. Esposito S, Bianchini S, Dellepiane RM, Principi N. (2016). Vaccines and Kawasaki disease. Expert Rev Vaccines. 15: 417-424. https://doi.org/10.1586/14760584.2016.1128329; PMid:26634312

15. Japanese Circulation Society Joint Working Group: JCS/JSCS (2020). Guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. URL: https://www.jstage.jst.go.jp/article/circj/84/8/84_CJ-19-1094/_pdf/-char/en.

16. Jennette JC, Falk RJ, Bacon PA et al. (2013). 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65: 1-11. https://doi.org/10.1007/s10157-013-0869-6; PMid:24072416 PMCid:PMC4029362

17. Juurlink DN. (2007, Aug 14). Drug interactions with warfarin: what clinicians need to know. CMAJ. 177(4): 369-371. https://doi.org/10.1503/cmaj.070946; PMid:17698826 PMCid:PMC1942100

18. Kanegaye JT, Van Cott E, Tremoulet AH, Salgado A, Shimizu C, Kruk P et al. (2013). Lymph-node-first presentation of Kawasaki disease compared with bacterial cervical adenitis and typical Kawasaki disease. J Pediatr. 162: 1259-1263.e2. https://doi.org/10.1016/j.jpeds.2012.11.064; PMid:23305955 PMCid:PMC3637400

19. Klymyshyn Yu. Datsko O. Stepanovskyy Yu. Nagao Y. Nagayama Y et al. (2023). A Ukrainian infant with giant coronary aneurysms: A case report and literature review. Clinical Case Reports. 11; 5. https://doi.org/10.1002/ccr3.7301; PMid:37151939 PMCid:PMC10160427

20. Kobayashi T, Ayusawa M, Suzuki H, Abe J, Ito S, Kato T et al. (2020, Oct). Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). Pediatr Int. 62(10): 1135-1138. Epub 2020 Oct 1. https://doi.org/10.1111/ped.14326; PMid:33001522

21. Lin KH, Chang SS, Yu CW, Lin SC, Liu SC, Chao HY et al. (2015). Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis. BMJ Open. 5: e006703. https://doi.org/10.1136/bmjopen-2014-006703; PMid:25872939 PMCid:PMC4401842

22. Maddox RA, Holman RC, Uehara R, Callinan LS, Guest JL, Schonberger LB et al. (2015). Recurrent Kawasaki disease: USA and Japan. Pediatr Int. 57: 1116-1120. https://doi.org/10.1111/ped.12733; PMid:26096590 PMCid:PMC4676732

23. Malska A, Kurilyak O, Nakonechna L, Klymyshyn Y, Stogova O et al. (2024). Features of diagnosis of incomplete Kawasaki disease in young children. A clinical case of Kawasaki disease with the formation of giant coronary artery aneurysms. Child's health. 19(2): 99-106. https://doi.org/10.22141/2224-0551.19.2.2024.1682

24. Manlhiot C, Brandao LR, Somji Z et al. (2010). Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients 2021 Japanese Society of Pediatric Cardiology and Cardiac Surgery with severe coronary artery abnormalities. Pediatr Cardiol. 31: 834-842. https://doi.org/10.1007/s00246-010-9715-8; PMid:20431996

25. Manlhiot C, Millar K, Golding F, McCrindle BW. (2010). Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol. 31: 242-249. https://doi.org/10.1007/s00246-009-9599-7; PMid:20024653

26. McCrindle BW, RowleyAH, NewburgerJW et al. (2017). Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 135: e927-999. https://doi.org/10.1161/CIR.0000000000000484; PMCid:PMC5664211

27. Miura M, Ayusawa M, Fukazawa R et al. (2020). The Guidelines on Acute Stage Kawasaki Disease Treatment. Pediatric Cardiology and Cardiac Surgery. 36(S1): S1.1-S1.29. doi: 10.9794/jspccs.36.S1.1

28. Miura M, Kobayashi T, Kaneko T et al. (2018). Association of severity of coronary artery aneurysms in patients with Kawasaki disease and risk of later coronary events. JAMA Pediatr. 172: e180030. Epub 2018 May 7. https://doi.org/10.1001/jamapediatrics.2018.0030; PMid:29507955 PMCid:PMC5875323

29. Oates-Whitehead RM, Baumer JH, Haines L et al. (2003). Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 4: CD004000. https://doi.org/10.1002/14651858.CD004000; PMid:14584002 PMCid:PMC6544780

30. Printz BF, Sleeper LA, Newburger JW, Minich LL, Bradley T, Cohen MS et al. (2011). Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol. 57: 86-92. https://doi.org/10.1016/j.jacc.2010.08.619; PMid:21185506 PMCid:PMC3577068

31. Poon LK, Lun KS, Ng YM. (2000). Facial nerve palsy and Kawasaki disease. Hong Kong Med J. 6: 224-226.

32. Sleeper LA et al. (2011). Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. The Journal of pediatrics. 158; 5: 831-835.e3. https://doi.org/10.1016/j.jpeds.2010.10.031; PMid:21168857 PMCid:PMC3075321

33. Son MBF, Gauvreau K, Tremoulet AH et al. (2019). Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. J Am Heart Assoc. 8: e011319. https://doi.org/10.1161/JAHA.118.011319; PMid:31130036 PMCid:PMC6585355

34. Sugahara Y, Ishii M, Muta H et al. (2008). Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol. 29: 398-401. https://doi.org/10.1007/s00246-007-9132-9; PMid:18027010

35. Sumitomo N, Karasawa K, Taniguchi K, Ichikawa R, Fukuhara J, Abe O et al. (2008). Association of sinus node dysfunction, atrioventricular node conduction abnormality and ventricular arrhythmia in patients with Kawasaki disease and coronary involvement. Circ J. 72: 274-280. https://doi.org/10.1253/circj.72.274; PMid:18219166

36. Takahashi K, Oharaseki T, Yokouchi Y, Yamada H, Shibuya K, Naoe S. (2012). A half-century of autopsy results-incidence of pediatric vasculitis syndromes, especially Kawasaki disease. Circ J. 76: 964-970. https://doi.org/10.1253/circj.CJ-11-0928; PMid:22313802

37. Takahashi T, Sakakibara H, Morikawa Y et al. (2015). Development of coronary artery lesions in indolent Kawasaki disease following initial spontaneous defervescence: a retrospective cohort study. Pediatr Rheumatol. 13: 44. https://doi.org/10.1186/s12969-015-0042-8; PMid:26530040 PMCid:PMC4632407

38. Tsuda E, Hamaoka K, Suzuki H et al. (2014). A survey of the 3-decade outcome for patients with giant aneurysms caused by Kawasaki disease. Am Heart J. 167: 249-258. https://doi.org/10.1016/j.ahj.2013.10.025; PMid:24439987

39. Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H. (2010). Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site. Pediatr Infect Dis J. 29: 430-433. https://doi.org/10.1097/INF.0b013e3181cacede; PMid:20032807